- Location
Tyrosine Kinase Inhibitors
"-
The FDA Has Approved Nexavar for The Treatment of Locally Recurrent or Metastatic
Nov 26, 2013Germany-based Bayer HealthCare and US-based Onyx Pharmaceuticals have announced that the US Food and Drug Administration (FDA) has approved Nexavar (sorafenib), an oral multi-kinase inhibitor, for the treatment of patients with ...
-
Ignyta Has Entered Into a License Agreement with Nerviano Medical Sciences
Nov 6, 2013US-based biotechnology firm Ignyta has entered into a license agreement with Nerviano Medical Sciences (Nerviano), under which Ignyta will get exclusive global development and marketing rights of tyrosine kinase inhibitors RXDX-101 and ...
Tags: Ignyta, Tyrosine Kinase Inhibitors
-
EMA Has Received an Application From Bayer HealthCare for Marketing Authorization
Sep 10, 2013The European Medicines Agency (EMA) has received an application from Bayer HealthCare for marketing authorization of its oral multi-kinase inhibitor, regorafenib, for the treatment of patients with gastrointestinal stromal tumors (GlST). ...
-
EC Granted Conditional Marketing Authorization for Bosutinib Anti-Cancer Drug in The EC
Apr 1, 2013The European Commission (EC) has granted conditional marketing authorization for Pfizer's Bosulif (bosutinib) anti-cancer drug in the European Union (EU). Bosulif is authorized in Europe for the treatment of adult patients with chronic ...
Tags: Pfizer Bosulif, cancer drug, drug
-
Labceutics Has Signed a Agreement with Asuragen to Conduct a Quality Assurance Study
Mar 14, 2013Labceutics has signed a agreement with Asuragen to conduct an international multi-center quality assurance study on the standardization of BCR-ABL1 quantitative measurements on the International Scale (IS). Participating laboratories ...
Tags: Labceutics, Asuragen, Conduct Pan European Study, CML
-
Proacta Announced FDA Approval of Investigational New Drug Application for PR610
Dec 6, 2012Proacta, a San Diego based biotechnology company, has announced FDA approval of investigational new drug (IND) application for PR610, a hypoxia-activated irreversible multi-kinase inhibitor, for the treatment of cancer. With the IND ...
Tags: investigational new drug, IND
-
Cytocell Unveiled a ROS1 Breakapart FISH Probe Test for Non-Small-Cell Lung Cancer
Dec 5, 2012Cytocell, a developer of fluorescence in situ hybridization (FISH) probes for use in cancer analysis, has unveiled a ROS1 Breakapart FISH probe test for non-small-cell lung cancer (NSCLC). The molecular cytogenetic test, which utilizes ...
-
Teva Pharmaceutical Received US FDA Approval for Synribo Injection
Nov 28, 2012Teva Pharmaceutical has received US Food and Drug Administration(FDA)approval for Synribo injection to treat adult patients with chronic phase(CP)or accelerated phase(AP)chronic myeloid leukemia(CML)with resistance and/or intolerance to ...
Tags: Teva Synribo Injection, US FDA, Teva Pharmaceutical, chronic phase
